Susquehanna International Group, LLP Arca Biopharma, Inc. Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$2.13 - $25.68 $183,810 - $2.22 Million	86,296 Added 37.86%	314,213 $647,000
Q2 2022 Aug 15, 2022	BUY	$2.2 - $2.53 $430,870 - $495,500	195,850 Added 610.75%	227,917 $568,000
Q4 2021 Feb 14, 2022	SELL	$2.15 - $2.97 $167,631 - $231,564	-77,968 Reduced 70.86%	32,067 $69,000
Q3 2021 Nov 15, 2021	BUY	$2.77 - $3.74 $22,957 - $30,997	8,288 Added 8.15%	110,035 $326,000
Q2 2021 Aug 11, 2021	SELL	$3.06 - $3.9 $14,856 - $18,934	-4,855 Reduced 4.55%	101,747 $355,000
Q1 2021 May 17, 2021	BUY	$3.48 - $5.3 $258,762 - $394,092	74,357 Added 230.6%	106,602 $389,000
Q4 2020 Feb 16, 2021	BUY	$3.74 - $5.18 $120,596 - $167,029	32,245 New	32,245 $129,000

280K

Ticker ABIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,410,100
Description
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydr...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.